{
    "clinical_study": {
        "@rank": "159881", 
        "arm_group": [
            {
                "arm_group_label": "Saline Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "2 of 8 subjects in each dose cohort will receive normal saline as a single intravenous infusion"
            }, 
            {
                "arm_group_label": "NCTX", 
                "arm_group_type": "Experimental", 
                "description": "6 of 8 subjects in each dose cohort will receive NCTX (PEGylated Liposomal Iodixanol Injection) as a single intravenous infusion"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a randomized, double-blind, single dose, dose-escalation study to evaluate the\n      safety, tolerability, and pharmacokinetics of NCTX (PEGylated Liposomal Iodixanol Injection)\n      administered intravenously to healthy volunteers. In addition, computed tomography (CT)\n      scans will be acquired to measure radiographic density in regions of interest (ROI) at times\n      from 3-5 hours and up to 72 hours following NCTX administration."
        }, 
        "brief_title": "Single Dose Safety, Tolerability and Pharmacokinetic Study of NCTX in Healthy Volunteers", 
        "completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Healthy Volunteers", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy, nonsmoking men and women 18 to 55 years of age\n\n          -  Body Mass Index (BMI) between 18.5 and 30.0 kg/m2\n\n          -  Serum creatinine within normal range and calculated creatinine clearance of 80\n             mL/min/1.73 m2 or greater\n\n        Exclusion Criteria:\n\n          -  Concurrent enrollment in another clinical trial or treatment with any investigational\n             products or therapies within 30 days prior to dosing\n\n          -  History of infusion reactions to liposomes, nanoparticles, monoclonal antibodies, or\n             intravenously administered materials\n\n          -  History of allergic/anaphylactoid-like reactions attributed to iodinated contrast\n             agents or other components of the formulation\n\n          -  Disturbances in normal fat metabolism, or total cholesterol greater than 240 mg/dL\n\n          -  Pregnant or nursing women\n\n          -  Exposure to significant radiation within 1 year, or previous CT scan within 5 years\n             prior to check-in"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "56", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 12, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02063594", 
            "org_study_id": "MARV2013-CP-001"
        }, 
        "intervention": [
            {
                "arm_group_label": "NCTX", 
                "description": "Single dose of NCTX (PEGylated Liposomal Iodixanol Injection) administered at escalating doses from 9 mg I/kg up to 110 mg I/kg", 
                "intervention_name": "NCTX (PEGylated Liposomal Iodixanol Injection)", 
                "intervention_type": "Drug", 
                "other_name": "NCTX"
            }, 
            {
                "arm_group_label": "Saline Placebo", 
                "description": "Single dose of 0.9% Sodium Chloride Injection, USP administered similarly and at an equivalent dose volume as the active drug", 
                "intervention_name": "Saline Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Iodixanol", 
            "Iodinated Contrast", 
            "Liposome", 
            "Computed Tomography", 
            "X-ray Imaging", 
            "Blood pool agent", 
            "Biomarker"
        ], 
        "lastchanged_date": "March 6, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Overland Park", 
                    "country": "United States", 
                    "state": "Kansas", 
                    "zip": "66211"
                }, 
                "name": "Quintiles Phase 1 Services"
            }, 
            "investigator": {
                "last_name": "Philip Leese, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Phase 1 Single Dose, Double-blind, Dose-escalation, Safety, Tolerability and Pharmacokinetic Study of NCTX (PEGylated Liposomal Iodixanol Injection) in Healthy Volunteers", 
        "overall_contact": {
            "email": "karen.macleod@marvalpharma.com", 
            "last_name": "Karen MacLeod", 
            "phone": "207-452-2039"
        }, 
        "overall_official": {
            "affiliation": "Quintiles Phase 1 Services", 
            "last_name": "Philip T Leese, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Assessment of safety by clinical laboratory parameters, vital sign measurements, electrocardiograms, and adverse event monitoring", 
            "safety_issue": "Yes", 
            "time_frame": "Baseline and up to and including 28 days post drug administration"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02063594"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Maximum blood concentration (Cmax), half-life (t1/2), and  ratio of free to encapsulated circulating iodixanol", 
                "safety_issue": "No", 
                "time_frame": "Baseline and up to 28 days post drug administration"
            }, 
            {
                "measure": "Radiographic density in ROIs by abdominal CT imaging", 
                "safety_issue": "No", 
                "time_frame": "From 3-5 hours and up to 72 hours following NCTX administration"
            }
        ], 
        "source": "Marval Pharma Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Marval Pharma Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}